PET hypoxia imaging with FAZA: Reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 2, 2013, Pages 186-197

  Busk, M ^a   Mortensen, L S ^a   Nordsmark, M ^a   Overgaard, J ^a   Jakobsen, S ^a   Hansen, K V ^a   Theil, J ^a   Kallehauge, J F ^a   D'Andrea, F P ^a   Steiniche, T ^a   Horsman, M R ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Hypoxia; Hypoxia targeting; PET; Radiotherapy; Reproducibility

Indexed keywords

FLUOROAZOMYCIN ARABINOSIDE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CERVICAL SQUAMOUS CELL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REFERENCE VALUE; REOXYGENATION; REPRODUCIBILITY; SQUAMOUS CELL CARCINOMA; TISSUE SECTION; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA;

ANIMALS; ANOXIA; BODY WEIGHT; CELL LINE, TUMOR; COLLAGEN; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG COMBINATIONS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LAMININ; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; PROTEOGLYCANS; RADIOTHERAPY; UTERINE CERVICAL NEOPLASMS;

EID: 84874108264     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2258-x     Document Type: Article

References (39)

1. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist. 2004;9 Suppl 5:4-9.
2. Olive PL. Radiation-induced reoxygenation in the SCCVII murine tumour: evidence for a decrease in oxygen consumption and an increase in tumour perfusion. Radiother Oncol. 1994;32:37-46.
3. Crokart N, Jordan BF, Baudelet C, et al. Early reoxygenation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions. Int J Radiat Oncol Biol Phys. 2005;63:901-10.
4. Dunst J, Hansgen G, Lautenschlager C, Fuchsel G, Becker A. Oxygenation of cervical cancers during radiotherapy and radiotherapy + cis-retinoic acid/interferon. Int J Radiat Oncol Biol Phys. 1999;43:367-73.
5. Harriss W, Bezak E, Yeoh E, Hermans M. Measurement of reoxygenation during fractionated radiotherapy in head and neck squamous cell carcinoma xenografts. Australas Phys Eng Sci Med. 2010;33:251-63.
6. Stadler P, Feldmann HJ, Creighton C, Kau R, Molls M. Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer. Radiother Oncol. 1998;48:157-64.
7. Santiago A, Eicheler W, Bussink J, et al. Effect of cetuximab and fractionated irradiation on tumour micro-environment. Radiother Oncol. 2010;97:322-9.
8. Yaromina A, Kroeber T, Meinzer A, et al. Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts. Int J Radiat Oncol Biol Phys. 2011;80:1205-13.
9. Eschmann SM, Paulsen F, Bedeshem C, et al. Hypoxia-imaging with (18)F-misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol. 2007;83:406-10.
10. Achermann RE, Ohlerth SM, Rohrer BC, et al. Oxygenation of spontaneous canine tumors during fractionated radiation therapy. Strahlenther Onkol. 2004;180:297-305.
11. Thames Jr HD, Peters LJ, Withers HR, Fletcher GH. Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. Int J Radiat Oncol Biol Phys. 1983;9:127-38.
12. Horsman MR, Overgaard J. Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen. Radiother Oncol. 2004;70:301-9.
13. Janssens GO, Rademakers SE, Terhaard CH, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol. 2012;30:1777-83.
14. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol. 1996;6:10-21.
15. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25:4066-74.
16. Beck R, Roper B, Carlsen JM, et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med. 2007;48:973-80.
17. Reddy SB, Williamson SK. Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs. 2009;18:77-87.
18. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys. 2007;68:291-300.
19. Toustrup K, Sorensen BS, Nordsmark M, et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 2011;71:5923-31.
20. Nehmeh SA, Lee NY, Schroder H, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:235-42.
21. Lin Z, Mechalakos J, Nehmeh S, et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys. 2008;70:1219-28.
22. Mortensen LS, Busk M, Nordsmark M, et al. Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: a preclinical study. Radiother Oncol. 2011;99:418-23.
23. Busk M, Horsman MR, Jakobsen S, et al. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys. 2008;70:1202-12.
24. Busk M, Walenta S, Mueller-Klieser W, et al. Inhibition of tumor lactate oxidation: consequences for the tumor microenvironment. Radiother Oncol. 2011;99:404-11.
25. Dewhirst MW, Kimura H, Rehmus SW, et al. Microvascular studies on the origins of perfusion-limited hypoxia. Br J Cancer Suppl. 1996;27:S247-51.
26. Lanzen J, Braun RD, Klitzman B, Brizel D, Secomb TW, Dewhirst MW. Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res. 2006;66:2219-23.
27. Baudelet C, Ansiaux R, Jordan BF, Havaux X, Macq B, Gallez B. Physiological noise in murine solid tumours using T2*-weighted gradient-echo imaging: a marker of tumour acute hypoxia? Phys Med Biol. 2004;49:3389-411.
28. Baudelet C, Cron GO, Ansiaux R, et al. The role of vessel maturation and vessel functionality in spontaneous fluctuations of T2*-weighted GRE signal within tumors. NMR Biomed. 2006;19:69-76.
29. Brurberg KG, Benjaminsen IC, Dorum LM, Rofstad EK. Fluctuations in tumor blood perfusion assessed by dynamic contrast-enhanced MRI. Magn Reson Med. 2007;58:473-81.
30. Magat J, Jordan BF, Cron GO, Gallez B. Noninvasive mapping of spontaneous fluctuations in tumor oxygenation using 19F MRI. Med Phys. 2010;37:5434-41.
31. Chen L, Zhang Z, Kolb HC, Walsh JC, Zhang J, Guan Y. 18F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with 18F-FMISO. Nucl Med Commun. 2012;33:1096-1102.
32. Busk M, Horsman MR, Jakobsen S, et al. Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast? Radiother Oncol. 2009;92:429-36.
33. Busk M, Munk OL, Jakobsen S, et al. Assessing hypoxia in animal tumor models based on pharmacokinetic analysis of dynamic FAZA PET. Acta Oncol. 2010;49:922-33.
34. Tran LB, Bol A, Labar D, et al. Hypoxia imaging with the nitroimidazole (18)F-FAZA PET tracer: a comparison with OxyLite, EPR oximetry and (19)F-MRI relaxometry. Radiother Oncol 2012. doi: 10.1016/j.radonc.2012.04.011
35. Tseng JR, Dandekar M, Subbarayan M, et al. Reproducibility of 3′-deoxy-3′-(18)F-fluorothymidine microPET studies in tumor xenografts in mice. J Nucl Med. 2005;46:1851-7.
36. Dandekar M, Tseng JR, Gambhir SS. Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med. 2007;48:602-7.
37. Chaplin DJ, Trotter MJ, Skov KA, Horsman MR. Modification of tumour radiation response in vivo by the benzamide analogue pyrazinamide. Br J Cancer. 1990;62:561-6.
38. Horsman MR, Chaplin DJ, Overgaard J. Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. Cancer Res. 1990;50:7430-6.
39. Wang K, Yorke E, Nehmeh SA, Humm JL, Ling CC. Modeling acute and chronic hypoxia using serial images of 18F-FMISO PET. Med Phys. 2009;36:4400-8.